Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Dialysable leukocyte extracts modify the course of experimental paracoccidioidomycosis in the Syrian hamster

Abstract

The effect of dialysable leukocyte extracts (DLE) obtained from hamsters immunized withParacoccidioides brasiliensis (immune DLE) and from non-immunized hamsters (non-immune DLE) was studied in hamsters inoculated withP. brasiliensis by the intratesticular route. Treatment with immune or non-immune DLE was started during the third week of infection and was repeated at 7, 11, 15 and 19 weeks. A group of untreated infected animals was used as control. Animals were submitted to the delayed hypersensitivity skin test toP. brasiliensis antigen (PbAg) in vivo and assayed in vitro by the macrophage migration inhibition test in the presence of Phytohemagglutinin (PHA) and PbAg and by immunodiffusion for specific antibody. The animals were sacrificed at 4, 8, 12, 16 and 20 weeks. The morphology and extension of the lesions were studied at the inoculation site, and in lymph nodes, lungs, liver, spleen and kidneys. In contrast to the controls, animals treated with both DLEs maintained a positive cell-mediated immune response throughout the experiment and developed less extensive infection with a significantly lower number of fungi in the lesions. The results suggest that immune and non-immune DLE preparations modified the evolution of experimental paracoccidioidomycosis with equal efficiency. This similarity may be explained by the immunoregulatory activities of both extracts.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Fudenberg HH. Transfer factor: An update. Proc Soc Exp Biol Med 1985; 178: 327–32.

  2. 2.

    Wilson GB, Fudenberg HH, Keller RH. Guidelines for immunotherapy of antigen sepcific defects with transfer factor. J Clin Lab Immunol 1984; 13: 51–58.

  3. 3.

    Mazaheri R, Hamblin AS, Zuckerman AJ. Cell-mediated immunity: Correlation of mixed-leucocyte-macrophage migration inhibition with delayed-type hypersensitivity after immunization and donor-specific transfer of cell migration inhibition by dialyzable leucocyte extract. Cell Immunol 1983; 82: 147–62.

  4. 4.

    Klesius PH, Fudenberg HH. Bovine transfer factor: In vivo transfer of cell-mediated immunity to cattle with alcohol precipitates. Clin Immunol Immunopathol 1977; 8: 238–46.

  5. 5.

    Giambrone JJ, Klesius PH, Yu H. Adoptive transfer of delayed wattle reactivity in chickens with a dialyzable leukocyte extract containing transfer factor. Poult Sci 1983; 62: 767–71.

  6. 6.

    Simon MR, Silva J, Freier D, Bruner J, Williams R. Tuberculin-specific transfer factor in dogs. Infect Immun 1977; 18: 73–77.

  7. 7.

    Peraçoli MTS, Montenegro MR, Soares AMVC, Mota NGS. Transfer of the cell-mediated immunity toParacoccidioides brasiliensis in hamsters with dialysable leukocyte extracts. J Med Vet Mycol 1990; 28: 39–50.

  8. 8.

    Smith RA, Esa A, Stiff M. Transfer ofSalmonella resistance and delayed hypersensitivity with murine-derived transfer factor. Infect Immun 1982; 36: 271–76.

  9. 9.

    Tsang KY, Fudenberg HH, Pan JF. Transfer of osteosarcoma-specific cell-mediated immunity in hamsters by rabbit dialyzable leukocyte extracts. Cell Immunol 1985; 90: 295–302.

  10. 10.

    Liburd EM, Pabst HF, Armstrong WD. Transfer factor in rat coccidiosis. Cell Immunol 1972; 5: 487–89.

  11. 11.

    Ross JG, Hallyday WG. Investigations of transfer factor activity in immunity toOstertagia circumcincta andTrichostrongylus colubriformis infections in sheep. Int J Parasitol 1979; 9: 281–84.

  12. 12.

    Olson GB, Drube CG. Modulation of influenza in mice by transfer factor therapy. J Reticuloendothel Soc 1978; 24: 589–99.

  13. 13.

    Kita E, Matsuda Y, Matsuda K, Kashiba S. Separate transfer of mouse protection and delayed-type hypersensitivity withSalmonella typhimurium transfer factor. Cell Immunol 1984; 87: 528–37.

  14. 14.

    Sen P, Smith JK, Buse M, Hsieh HC, Lavenhar MA, Lintz D, Louria DB. Modification of an experimental mouse Candida infection by human dialyzable leukocyte extract. Sabouraudia 1982; 20: 85–93.

  15. 15.

    Mota NGS, Rezkallah-Iwasso MT, Peraçoli MTS, Audi RC, Mendes RP, Marcondes J, Marques SA, Dillon NL, Franco MF. Correlation between cell-mediated immunity and clinical forms of paracoccidioidomycosis. Trans R Soc Trop Med Hyg 1985; 79: 765–72.

  16. 16.

    Musatti CC, Rezkallah MT, Mendes E, Mendes NF. In vivo and in vitro evaluation of cell-mediated immunity in patients with paracoccidoidomycosis. Cell Immunol 1976; 24: 365–78.

  17. 17.

    Tani E, Franco MF, Peraçoli MTS, Montenegro MR. Experimental pulmonary paracoccidioidomycosis in the Syrian hamster: Morphology and correlation of lesions with immune response. J Med Vet Mycol 1987; 25: 291–300.

  18. 18.

    Iabuki K, Montenegro MR. Experimental paracoccidioidomycosis in the Syrian hamster: Morphology, ultra-structure and correlation of lesions with presence of specific antigens and serum level and antibody. Mycopathologia 1979; 67: 31–41.

  19. 19.

    Peraçoli MTS, Mota NGS, Montenegro MR. Experimental paracoccidioidomycosis in the Syrian hamster: Morphology and correlation of lesions with humoral and cell-mediated immunity. Mycopathologia 1982; 79: 7–17.

  20. 20.

    Calich VLG, Purchio A, Paula CR. A new fluorescent viability test for fungi cells. Mycopathologia 1978; 66: 175–77.

  21. 21.

    Fava Netto C, Vegas VS, Sciannamea IM, Guarnieri DB. Antígeno polissacarídico doParacoccidioides brasiliensis: Estudo do tempo de cultivo doP. brasiliensis necessário ao preparo do antígeno. Rev Inst Med Trop S Paulo 1969; 11: 177–81.

  22. 22.

    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265–75.

  23. 23.

    Smith JK, Hsieh C. Transfer factor. North Shore Univ Hosp Clin J 1978; 1: 27–37.

  24. 24.

    Gross PA, Patel C, Spitler LE. Disseminated crytptococosis treated with transfer factor. J Am Med Assoc 1978; 240: 2460–62.

  25. 25.

    Dwyer JM, Gerstenhaber BJ, Dobuler KJ. Clinical and immunologic response to antigen-specific transfer factor in drug-resistant infection withMycobacterium xenopi. Am J Med 1983; 74: 161–68.

  26. 26.

    Mackie RM.Mucocutaneous candidiasis responsive to transfer factor therapy. J R Soc Med 1979; 72: 926–27.

  27. 27.

    Rosenfeld F, Viza D, Phillips J, Vich JM, Binet O, Aron-Brunetiere R. Traitement des infections herpétiques par le facteur de transfert. Presse Méd 1984; 13: 537–40.

  28. 28.

    Estevez ME, Sen L, Diez R, Negroni R, Gioseffi O. Evaluación inmunológica del factor de transferencia en el tratamiento de la mucocandidíasis crónica. Bol Acad Nac Med Buenos Aires 1981; 59: 285–96.

  29. 29.

    Leser PG, Margarido L, Belda W, Sartori SG, Hares WA, Freire CAR, Fleury R, Montenegro MR, Leser W, Naspitz CK. Cell-mediated immunity in patients withVirchowian hanseniasis before and after treatment with transfer factor. Hansenol Int 1980; 5: 3–27.

  30. 30.

    Xie L, Kang F, Du Y. E-rosette forming count determination and transfer factor treatment in herpetic simplex keratitis. Chin Med J 1983; 96: 860–64.

  31. 31.

    Fudenberg HH, Fudenberg HH. Transfer factor: past, present and future. Ann Rev Pharmacol Toxicol 1989; 29: 475–516.

  32. 32.

    Ashorn RGI, Vandenbark AA, Acott KM, Krohn KJE. Dialysable leukocyte extracts (Transfer factor) augment nonspecifically keyhole limpet haemocyanin and horse-shoe crab haemocyanin skin reactivity in unimmunized human recipients. Scand J Immunol 1986; 23: 161–67.

  33. 33.

    Metzger M, Podwinska J, Smogor W. Development of immunological responsiveness and resistance to infection withTreponema pallidum in rabbits given immune lymphocyte preparations. Arch Immunol Ther Exp 1980; 28: 329–36.

  34. 34.

    Da Costa JC, Gonçalves RP, Pagano PMG, Bechelli LM. Ultrastructure of lymphocytes from patients with paracoccidoidomycosis in the lymphocyte transformation test by phytohemagglutinin. Mycopathologia 1986; 93: 155–61.

  35. 35.

    Arango M, Oropeza F, Anderson O, Contreras C, Bianco M, Yarzabal L. Circulating immune complexes and in vitro reactivity in paracoccidioidomycosis. Mycopathologia 1982; 79: 152–58.

  36. 36.

    Chequer-Bou-Habib DC, Oliveira-Netto MP, Ferreira Da Cruz MT, Galvão-Castro B. The possible role of circulating immunecomplexes in the deficiency of cell-mediated immunity in paracoccidioidomycosis. Braz J of Med Biol Res 1989; 22: 205–12.

  37. 37.

    Franco M, Mendes RP, Moscardi-Bacchi M, Rezkallah-Iwasso MT, Montenegro MR. Paracoccidioidomycosis. Baill Clin Trop Med Commun Dis 1989; 4: 185–220.

  38. 38.

    Togawa A, Oppenheim JJ, Kirkpatrick CH. Ability of dialysates containing transfer factor to induce lymphocyte activating factor by human mononuclear cells. Cell Immunol 1979; 45: 133–41.

  39. 39.

    Houssiau FA, Coulie PG, Olive D, Van Snick J. Synergistic activation of human T cells by Interleukin-1 and Interleukin-6. Eur J Immunol 1988; 18: 653–56.

  40. 40.

    Tosato G, Miller, J. Marti G, Pike SE. Accessory function of Interleukin-1 and Interleukin-6: Peripheral costimulation of T4 positive lymphocytes. Blood 1990; 75: 992–1030.

Download references

Author information

Correspondence to Dr M. T. S. Peraçoli.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Peraçoli, M.T.S., Rezkallah-Iwasso, M.T., Mota, N.G.S. et al. Dialysable leukocyte extracts modify the course of experimental paracoccidioidomycosis in the Syrian hamster. Mycopathologia 121, 149–156 (1993). https://doi.org/10.1007/BF01104070

Download citation

Key words

  • Paracoccidioidomycosis
  • Syrian hamster